ECOG-ACRIN EA5181

Official Title

Testing The Addition Of An Antibody To Standard Chemoradiation Followed By The Antibody For One Year To Standard Chemoradiation Followed By One Year Of The Antibody In Patients With Unresectable Stage III Non-Small Cell Lung Cancer

Study Purpose

To see if we can extend your life and/or prevent your tumor from coming back by adding a study drug durvalumab during chemotherapy and radiation therapy.

Diagnosis

Eligibility

Newly diagnosed stage III NSCLC unresectable, plan for chemo and RT

Patients must sign an approved informed consent and authorization permitting release of personal health information.

Intervention

• Group 1 (Arm A, Arm C): Patients will get the study drug, durvalumab (Arm A). Then will receive durvalumab once every 4 weeks for 1 year (Arm C).
• Group 2 (Arm B, Arm C): Patients will receive only standard chemo/radiation (Arm B). Then will receive durvalumab once every 4 weeks for 1 year (Arm C).